Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Caligan Partners LP 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Caligan Partners LP (CIK 1727492) reported $1.50B across 21 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: LQDA ($306.4M, 20.39%), RVMD ($183.0M, 12.18%), ABVX ($162.8M, 10.83%), PCVX ($119.7M, 7.97%), XENE ($81.0M, 5.39%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1LQDALIQUIDIA CORPORATION$306.4M20.39%8.1MHold
2RVMDREVOLUTION MEDICINES INC$183.0M12.18%1.9MAdded
3ABVXABIVAX SA$162.8M10.83%1.5MAdded
4PCVXVAXCYTE INC$119.7M7.97%2.1MAdded
5XENEXENON PHARMACEUTICALS INC$81.0M5.39%1.4MAdded
6MLYSMINERALYS THERAPEUTICS INC$75.1M5.00%2.8MTrimmed
7EXELEXELIXIS INC$66.6M4.43%1.6MHold
8CGONCG ONCOLOGY INC$60.9M4.05%900,000New
9TNGXTANGO THERAPEUTICS INC$50.4M3.35%2.4MTrimmed
10TYRATYRA BIOSCIENCES INC$48.9M3.25%1.3MAdded
11ADMAADMA BIOLOGICS INC$45.6M3.03%5.1MAdded
12SYRESPYRE THERAPEUTICS INC$44.3M2.95%878,127New
13LB PHARMACEUTICALS INC$34.6M2.30%1.4MNew
14VORVOR BIOPHARMA INC$34.3M2.29%1.9MAdded
15SABSSAB BIOTHERAPEUTICS INC$30.5M2.03%8.0MNew
16IVAINVENTIVA SA$27.6M1.84%5.0MAdded
17IRDOPUS GENETICS INC$27.6M1.84%6.1MNew
18MBXMBX BIOSCIENCES INC$25.3M1.69%848,590New
19AVTXAVALO THERAPEUTICS INC$24.4M1.62%1.6MAdded
20ANIKANIKA THERAPEUTICS INC$20.8M1.38%1.4MHold
21MAZEMAZE THERAPEUTICS INC$18.4M1.22%614,962Added
22VRCAVERRICA PHARMACEUTICALS INC$4.9M0.33%923,910Hold
23SNSESENSEI BIOTHERAPEUTICS INC$4.0M0.26%126,002New
24AGIOAGIOS PHARMACEUTICALS INC$3.0M0.20%90,000Hold
25AURAAURA BIOSCIENCES INC$1.5M0.10%229,864New

Source: SEC Form 13F filings · as of 2026-03-31